Our current research includes three arching themes:
I. Deterministic cell therapies enabled by iPS cells and CRISPR nucleases.
1. Engineered iPS cell-based therapies.
II. Genome wide modulation of human cell systems enabled by CRISPR nucleases.
1. Creation of cell therapies enabled by CRISPR nucleases and iPS cells (P-PAD-22-76) funded by RCL.
III. Gain of function cell therapies enabled by iPS cells and CRISPR nucleases.
1. CRISPR-Cas9 enabled cell-based therapeutics.
2. Advanced Nuclease-enabled Regenerative Medicine Therapies against cancer (NRMT - P-MIP-23-1) funded by RCL.